Madhav Sachar

Madhav Sachar

Auto-generated profile, based on publicly available information

Madhav Sachar

Elevar Therapeutics, Inc. Salt Lake City UT USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
MSMadhav Sachar
Madhav Sachar
KAKarl Elmo Anderson
Karl Elmo Anderson
XMXiaochao Ma
Xiaochao Ma
Protoporphyrin IX (PPIX) is ubiquitously present in all living cells in small amounts as a precursor of heme. PPIX has some biologic functions of its own, and PPIX-based strategies have been used for cancer diagnosis and treatment (the good). PPIX serves as the substrate for ferrochelatase, the final enzyme in heme biosynthesis, and its homeostasis is tightly regulated during heme synthesis. Accumulation of PPIX in human porphyrias can cause skin photosensitivity, biliary stones, hepatobiliary damage, and even liver failure (the bad and the ugly). In this work, we review the mechanisms that are associated with the broad aspects of PPIX. Because PPIX is a hydrophobic molecule, its disposition is by hepatic rather than renal excretion. Large amounts of PPIX are toxic to the liver and can cause cholestatic liver injury. Application of PPIX in cancer diagnosis and treatment is based on its photodynamic effects.

6 September 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
PWPengcheng Wang
Pengcheng Wang
MSMadhav Sachar
Madhav Sachar
JLJie Lu
Jie Lu
ASAmina I. Shehu
Amina I. Shehu
JZJunjie Zhu
Junjie Zhu
XMXiaochao Ma
Xiaochao Ma
The transporter ABCG2 determines phototoxicity and hepatotoxicity in erythropoietic protoporphyria.

20 July 2016 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
MSMadhav Sachar
Madhav Sachar
FLFeng Li
Feng Li
KLKe Liu
Ke Liu
PWPengcheng Wang
Pengcheng Wang
JLJie Lu
Jie Lu
XMXiaochao Ma
Xiaochao Ma

1 December 2015 in Biochemical Pharmacology
Verified
Journal Article
Closed access
KLKe Liu
Ke Liu
JYJiong Yan
Jiong Yan
MSMadhav Sachar
Madhav Sachar
XZXinju Zhang
Xinju Zhang
MGMing Guan
Ming Guan
XMXiaochao Ma
Xiaochao Ma

1 November 2020 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
MSMadhav Sachar
Madhav Sachar
VKVineet Kumar
Vineet Kumar
LGLars Christian Gormsen
Lars Christian Gormsen
OMOle Lajord Munk
Ole Lajord Munk
JUJashvant D Unadkat
Jashvant D Unadkat
Predicting transporter-mediated in vivo hepatic drug clearance (CL) from in vitro data (IVIVE) is important in drug development to estimate first in human dose and the impact of drug interactions and pharmacogenetics on hepatic drug CL. For IVIVE, one can use human hepatocytes and the traditional MGPGL (i.e. mg of protein content per gram of liver tissue) approach. However, this approach has been found to consistently under-predict the observed in vivo hepatic drug CL. Therefore, we hypothesized that using transporter-expressing cells and the relative expression factor (REF), determined using targeted quantitative proteomics, will accurately predict in vivo hepatic CL of drugs. We have successfully tested this hypothesis in rats with rosuvastatin, which is transported by hepatic OATPs. Here we tested this hypothesis for another drug and another transporter, namely OCT1- mediated hepatic distributional CL of metformin. First, we estimated the in vivo metformin hepatic sinusoidal uptake CL (CLh,s,in ) of metformin by reanalysis of previously published human positron emission tomography imaging data. Next, using the REF approach, we predicted the in vivo metformin CLh,s,in using OCT1-transporter expressing HEK293 cells or plated human hepatocytes. Finally, we compared this REF-based prediction with that using the MGPGL approach. The REF approach accurately predicted the in vivo metformin hepatic CLh,s,in while the MGPGL approach considerably under-predicted the in vivo metformin CLh,s,in . Based on these and previously published data the REF approach appears to be superior to the MGPGL approach for a diverse set of drugs transported by different transporters. Significance Statement This study is the first to use OCT1-expressing cells and plated hepatocytes to compare proteomics-informed REF approach with the traditional MGPGL approach to predict hepatic uptake CL of metformin in humans. The plasma membrane abundance corrected proteomics-informed REF approach accurately predicted the PET-imaged metformin hepatic uptake CL, whereas the MGPGL approach consistently underpredicted this CL.

21 January 2013 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
PDF file
MSMadhav Sachar
Madhav Sachar
XMXiaochao Ma
Xiaochao Ma
Widespread usage of herbs as supplements or medicines raises the potential of herb-drug interactions (HDIs). Basically, HDIs occur by pharmacokinetic and/or pharmacodynamic pathways. Nuclear receptors (NRs) are a class of transcription factors whose role in drug interactions has been defined. A large number of herbs activate NRs, resulting in HDIs. NR-mediated HDIs are similar to drug-drug interactions, but are more complicated because of the presence of multiple compounds in herbs. Dosage and therapeutic sequence as well as various other factors, including the patient’s gender, age, and genetic makeup, may affect outcomes of NR-mediated HDIs.